Gallstone Symptom Risk Calculator

Surgery is an important decision.

Evidence-Led Decision Support

Move beyond generalities. Understand the research.

Elevating the Standard of Care

Every patient’s journey with gallstone disease is unique, yet many treatment decisions are made without looking at the fine print. To provide a higher standard of care, I believe in Evidence-Based Precision—using high-quality research to navigate your choices.

Why this matters: Not all gallstones carry the same risk of causing an emergency while you wait. I developed this Interactive Evidence Explorer because I believe my patients deserve to understand the data behind the decision.

By analyzing the RELAPSTONE study (tracking 3,000+ patients who did not have surgery), we can see that specific profiles carry higher risks than others. Using this insight, I can offer you a consultation that isn't just about "booking a procedure," but about building a safe, prioritized clinical strategy tailored to your needs.

Consider bringing your report to your consultation with Mr. Rahman

Gallstone Evidence Explorer

Visualising the RELAPSTONE (2024) Multicentre Study Cohort.




Probability of remaining symptom-free
63.0%
at 12 Months Follow-up

Clinical Evidence Summary

Mr Saqib Rahman PhD FRCS

Consultant Biliary & Hernia Surgeon

Wessex Nuffield Hospital
Private Practice Service
Trial Reference: RELAPSTONE Multicentre Cohort (2024) Date:

1. Scenario Profile

    Probability of remaining symptom-free at 12 Months

    2. Visualised Outcomes (12-Month Kaplan-Meier)

    3. Consultation Notes

    Medical Evidence Note: This document is for educational purposes only. It visualises published research data from the RELAPSTONE (2024) study by applying multivariate Hazard Ratios (HR) to a baseline survival curve. It does not constitute a personalised clinical prediction or medical advice.
    • Evidence Source: The RELAPSTONE Study The data shown here is derived from a large-scale international multicentre study of 3,016 patients. The researchers identified several independent prognostic factors that were statistically associated with a higher likelihood of symptoms returning while waiting for surgery:

      • Stone Burden: In the study, patients with multiple gallstones had a higher recurrence rate (HR 1.19).

      • Liver Biochemistry (ALT): Elevated ALT levels at presentation were a key marker for relapse in the trial cohort (HR 1.22).

      • Age Trends: Data indicated that younger patients in the study often displayed higher symptomatic recurrence rates than older cohorts.

      • Ductal Clearance: A history of ERCP was found to be a protective factor within the research group.

    • Regulatory Statement & Purpose: This tool is an Interactive Clinical Reference intended for professional and patient education. It visualises population-level data from a published retrospective cohort and does not perform a personalised clinical risk prediction, diagnosis, or treatment recommendation.

      Limitations:‍ ‍Not a Medical Device: This tool provides a visual interface for peer-reviewed literature; it is not a validated medical device for individual prognosis.

      • Statistical Probability: The results represent trends within a specific research population. Individual outcomes vary based on anatomy, comorbidities, and clinical presentation.

      • Consultation Required: All symptomatic gallstones carry a baseline risk of complications. Use this report to facilitate a formal clinical consultation with Mr Saqib Rahman.

    The interactive tools on this site are for educational purposes only. They visualise population data from peer-reviewed clinical trials (RELAPSTONE 2024) and do not provide personalised medical diagnosis or treatment predictions. All surgical decisions must be made in consultation with Mr Saqib Rahman.

    Decided to proceed? Now that you understand your risks, use our Recovery Planner to see exactly when you can return to driving, work, and holidays after your operation.